Wyatt Technology Publishes Whitepaper on Protein Quality Control in High-Throughput Screening Studies
Wyatt Technology has published a new whitepaper outlining how to evaluate the solution quality of biotherapeutic candidates prior to screening via Surface Plasmon Resonance (SPR) or Bio Layer Interferometry (BLI). The DynaPro Plate Reader II. Analyte quality is critical to obtaining accurate and
meaningful measurements to select the most promising therapeutic candidates, so ensuring the quality of samples is a vital step in the screening process. The DynaPro highthroughput dynamic light scattering (HT-DLS) system provides an effective method of assessing sample materials using a non-invasive, non-pertubative optical technique.
SPR and BLI are popular techniques for high-throughput screening and discovery of biotherapeutic candidates. Impurities such as aggregates and foreign particles often affect measurements through noise, spurious signals and inaccurate active concentrations. In addition, owing to their size and the small apertures of the on-chip channels, particulates may cause blockage to occur in sensitive SPR microfluidics.
Dr Daniel Some, Principal Scientist at Wyatt Technology, commented: “Guaranteeing that samples are appropriate for SPR, BLI or ITC analyses is critical to proper binding screens. The rapid and automated quality assessment provided by the DynaPro Plate Reader II HT-DLS system ensures a valuable layer of quality control that would simply not be an option with manual, cuvette-based testing. When single binding experiments are needed, the DynaPro NanoStar microcuvette DLS system evaluates solution quality with as little as one microliter of sample.”
Requiring no fluidic handling, the DynaPro Plate Reader II HT-DLS system can quickly and effectively analyze protein quality in large sample populations with no concerns for carryover between samples. By automatically classifying samples as high, medium, and low quality, the DynaPro, in conjunction with DYNAMICS
data analysis, collection, and reporting software, provides intuitive visual analysis to quickly evaluate the suitability of each solution for reliable binding screens.
The DynaPro performs measurements in the same microwell plates as SPR and BLI highthroughput discovery screening platforms, saving researchers considerable time and effort in assessing the quality of large batches of biotherapeutic samples and ensuring accurate results. By presenting several example analyses, the whitepaper showcases the HT-DLS process and DYNAMICS visualizations that make quality control with the DynaPro system practically effortless
Related News
-
News CPHI Podcast Series: The power of proteins in antibody drug development
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development. -
News Amgen sues Samsung biologics unit over biosimilar for bone disease
Samsung Bioepis, the biologics unit of Samsung, has been issued a lawsuit brought forth by Amgen over proposed biosimilars of Amgen’s bone drugs Prolia and Xgeva. -
News CPHI Podcast Series: Why we need to consider women in clinical trials
The latest episode of the CPHI Podcast Series with Lucy Chard covers women's health, specifically women's representation in clinical trials, the associated bias, and the impacts on health for this population. -
News US FDA does not approve MDMA therapy for PTSD, requests more data
The MDMA-based therapeutic developed by Lykos Therapeutics, a California-based Public Benefit Corporation (PBC), has been reviewed and unapproved by the US FDA. The regulator has requested additional phase III trial data for further safety and efficacy... -
News Novartis and Viatris latest facing lawsuit over HeLa cell misuse
Global pharmaceutical companies Novartis and Viatris are the latest hit with a lawsuit claim pertaining to alleged misuse of the ‘HeLa’ cell line from the estate of woman whose cancerous tissue cells were taken without consent. -
News Sanofi invests billions into Frankfurt insulin production site
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production. -
News Novel oral Type 1 diabetes drug gains US FDA IND designation
A University of Alabama at Birmingham startup has gained FDA clearance for Investigational New Drug clinical trials for an oral Type 1 diabetes drug, a milestone for diabetes treatment. -
News A Day in the Life of a Vice President in R&D & Engineering
In the Day in the Life of Series, we've already had the chance to get to know a range of people in various roles in the pharma industry. In the latest interview we get a glimpse into the R&D side of things from Jennifer Sorrells, Vice Presiden...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance